Physician profile
Philip Todd Devane
NPI 1538150891
$9,379.23
in general payments reported to CMS, 2019-2025
67 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $414 · 2021: $1,541 · 2022: $1,948 · 2023: $1,708 · 2024: $1,707 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $764.31 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $731.41 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Lilly USA, LLC | $681.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $644.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $468.32 | 2019-2023 | Xifaxan, Trulance |
| Astellas Pharma US INC | $425.09 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $410.60 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $373.51 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $311.35 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $303.36 | 2019-2023 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $299.01 | 2019-2022 | |
| Pfizer INC. | $289.84 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.53 | 2019-2024 | Synjardy, Jardiance |
| Sanofi-Aventis U.S. LLC | $254.51 | 2019-2024 | |
| Boston Scientific Corporation | $223.26 | 2019-2023 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Devane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.